ELECTRONIC MEDICAL RECORDS: QUALITY CANCER CARE AND COST-EFFECTIVENESS

Ann D Colosia, PhD1; Shahnaz Khan, MPH1; Gerson Peltz, MD, MPH2; Gerhardt Pohl, PhD2; Esther Liu, PharmD, RAC2; James A Kaye, MD, DrPH3 1RTI Health Solutions, Research Triangle Park, NC, United States; 2Eli Lilly and Company, Indianapolis, IN, United States; 3RTI Health Solutions, Waltham, MA, United States

BACKGROUND

- There is a pressing need to evaluate and improve the quality and efficiency of cancer care in the United States due to associated cost increases 1/2
- · The Institute of Medicine recommended that information technology products replace most handwritten clinical data to remove impediments to care, such as records that are
 - Poorly organized
 - Illegible
 - Hard to retrieve 3
- · Quality of cancer care may improve with information technology products such as electronic medical records (EMRs).

OBJECTIVES

- · To identify the value of EMRs to providers in assessing and improving quality cancer care.
- To identify issues in cost and cost-effectiveness of EMRs from the provider perspective.

METHODS

- · Conducted systematic literature review about quality of cancer care in PubMed, Embase, and Cochrane Reviews; considered only articles published in English in the last 10 years.
- · Conducted supplemental review: searched PubMed and conference abstracts from the American Society of Clinical Oncology (ASCO) from 2005 to 2009.
- · Gave some leeway for potentially relevant subjects even if cancer was not the specific focus.
- Identified 16 sources RESULTS

Descriptive Studies

Four studies described the benefits and issues with EMR and drew the following conclusions:

- EMRs could monitor compliance with cancer guidelines.⁴
- · G2-clin, an EMR application system integrated into a hospital information system:
 - Satisfied requirements for procedure standardization and data distribution.
 - Allowed monitoring of numerous outcomes of care.⁵
- · To realize the potential of clinical decision support, EMR vendors must develop systems that can communicate with external modular niche programs.6
- · Much of hospital data transferred from point-of-care testing (POCT) devices is not integrated into EMR or other hospital or laboratory information systems for the following reasons:
 - Lack of interoperability of multiple devices with EMR or other information systems, all produced by multiple vendors.
 - Inability to capture manually read outcomes.

Stakeholder Perspectives

Three studies presented stakeholder perceptions on the impact of EMR on guality cancer care and drew the following conclusions:

- · In a systematic literature review, most studies found a neutral impact of EMR on patient satisfaction 8
- · EMR may be an essential component of cancer care by providing access to records, reducing unnecessary repeat of tests, and promoting patient safety. Most patients agreed to have EMRs 9
- A literature review of interview studies¹⁰ found that nurses perceived improved documentation with EMR, but they also had the following negative perceptions:
 - Not designed to fit with nurses' workflow
 - Takes time away from actual patient care
 - Does not provide a useful output for nurses.

Conto and Cont Reputito of EMR Table

Table 1. CO	sts and Cost Ben	ETITS OF EMIR		
Study/Setting	Key Points			
Costs and resource use associated with developing an EMR system adapted to evaluate tumor- and stage- specifice in oncology compliance in oncology as a oncology as a mechanism to improve quality cancer care ¹¹ HMO with 75,000 members	Direct costs: \$25,000 computer hardware \$25,000 computer hardware \$25,000 computer hardware \$10,000 centoment training \$48,400 Total Annualized operational costs: \$76,000 providers' time for entering data and continued EMR training \$22,500 check of brylacian and dathmistatifiles supervision \$20,000 senior administration coordination \$25,000 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 LT consultants and FMR maintenance fees. \$20,200 check data analysis \$5,500 check data analysis \$5,			
ENR adoption by the primary care in the primary care produces (mean produces) (mean produces) (mean too) (mean) (m	Initial costs: \$43,800 (software training and installation, hardware, lost revenues). Ongoing costs per provider per year: \$8,400 (maintenance,			
	Ongoing costs per provider per year: 38.400 (ministenance, aupport, replacement, dating, dhen). Time to recover EMR Initial and cumulative ongoing costs: would not recover cost of EMR. Average profits after cost recovery: 32.000 per provider per agent from increased coding levels and praster efficiency). Benefits to providers: More personal time, remote and inmediate access of records. Financial risk, 13.01 4 practices experienced considerable financial risk, 13.01 4 practices experiences and EMR system itsues resulting in total data to serveral weeks. 9 Practices had specific tamplates for quality improvement. 9 practices had specific total test to at least one type of chronic care formation. 24.5 practices had specific total test coding, 4 structure with more experience of LMM adoption results in coding-related gains because of the structure of the current trembursternet system, which rewards more extensive coding, A structure with more more the limited cality improvement use of EMR.			
	staff by almost 75%.	Savings (Percentage of Total Institution Expenses) 2.7% (excluding noncontrollable and capital costs) 3.4% (from physicians ordering 12.7% fewer tasks with subacquerus costs and shortened hospital stays) 2.2% (from 25% reduction of billing staff, 21 fewer days in accounts receivable, and 10% to 25% reduction of bad debts) 0.43% (from 75% decrease in outpatient labor costs) ef rom reduction of medical records		
	Conclusions: Implementing EMR use may take years and millions of dollars. Executives can make informed decisions about EMR use by conducting a cost-benefit analysis.			

Study/Setting	Key Points					
Using template in EMRs to improve documentation of	 Quality of care assessed in spring and fall using ASCO's Quality Oncology Practice Initiative (QOPI) survey, wQOPI is a program to improve quality of care. 					
care for cancer patients treated by Duke University's Hematology and Oncology fellows ¹⁴	 Attending and fellow physicians abstracted data from EMRs into the online QOPI tool; each abstraction took 15 minutes. 					
	 Spring QOPI survey identified areas needing improvement (i.e., documentation that needed to improve). 					
	· Template was created within the EMR to capture details of care for patients who were to receive chemotherapy					
	or biotherapy for lung or colorectal cancer.					
	 Between surveys, improvements were seen in the proportion of patients with a documented number of chemotherapy cycles (spring, 54%; fall, 96%) and documentation of pain assessment (spring, 78%; fall, 87%) and chemotherapy intent discussions (spring, 72%; fall, 86.5%). 					
	Conclusion: Documentation improved by incorporating the required template into the EMR.					
Evaluation of breast cancer guideline compliance at a multi-specialty institution	Goal: Assess the time and accuracy of physician and nonphysician reviews of EMRs for quality measure information regarding adherence to breast cancer guidelines.					
Guidelines assessed were	 NICCQ compliance: Number of quality measures with compliance < 85%: Physician reviews, 7 of 36; nonphysician reviews, 6 of 36 					
from the NICCQ and the NICCN ¹⁶	 Particle of quality measures with compliance < 55%. Physician reviews, 7 of 36, nonphysician reviews, 6 of 36 Percentage of patients receiving recommended care: Physician reviews, 91.5%; nonphysician reviews, 89.8%. NCCN guideline compliance: 					
	For preoperative workup, nonphysician reviews were more accurate than physician reviews; no other significant differences.					
	Average time for EMR review:					
	 Physicians reviews: NICCQ guideline measures, 6.3 minutes per chart; NCCN guideline measures, 6.8 minutes per chart. Nonphysician reviews: NICCQ guideline measures, 8.9 minutes per chart; NCCN guideline measures, 8.3 					
	minutes per chart.					
	Conclusions: Physicians conducted the reviews slightly faster than nonphysicians, but this difference was offset by the cost of the physicians' time. Compliance assessment between physicians and nonphysicians were similar, or even somewhat more accurate by nonphysicians.					
A community oncology	Patient tracking:					
practice in California	· 25% of 345 patients were seen	n in a hospital but not in the off	ice (reasons: insurance, tra	insfer of care, hospice,		
evaluated guideline compliance and quality care	no show).					
for colon cancer patients	Error tracking in records: • 9.6% of 345 patients' records with incorrect ICD code for diagnosis.					
before and after adopting EMR ¹⁶	 9.6% of 345 patients' records v No disease stage (N = 234), bit 					
EMR	Percentage of patients receive					
			-			
	Disease Stage	Before EMR	After EMR	P Value		
		4	44	NR 0.02		
		20	52	0.008		
	IV IV	20	75	0.6		
	Constructioner CMDs and have		element au data tiere en elékerinek			
	Conclusions: EMRs can be us needed to document reasons fo system would avoid incorrect da	ed to monitor compliance to na r instances of noncompliance.	Integration of EMR with the	explanatory codes are		
Implementation of EMR in an oncology department in Italy ¹⁷	needed to document reasons fo system would avoid incorrect dia Objective: Evaluate the perform Outcome assessed: Adherence	ed to monitor compliance to na r instances of noncompliance, agnosis code use by oncologis nance on OncoQual.	Integration of EMR with the ts or staff.	explanatory codes are a billing information		
oncology department in Italy ¹⁷ EMR includes a clinical	needed to document reasons fo system would avoid incorrect dia Objective: Evaluate the perform Outcome assessed: Adherence breast cancer.	ed to monitor compliance to na r instances of noncompliance. agnosis code use by oncologis nance on OncoQual. e to ASCO recommendations of	Integration of EMR with the ts or staff.	explanatory codes are a billing information		
oncology department in Italy17	needed to document reasons fo system would avoid incorrect dia Objective: Evaluate the perform Outcome assessed: Adherence breast cancer. Measures: Percentage of patier	ed to monitor compliance to na r instances of noncompliance. agnosis code use by oncologis nance on OncoQual. e to ASCO recommendations of	Integration of EMR with the ts or staff.	explanatory codes are a billing information		
oncology department in Italy ¹⁷ EMR includes a clinical instrument panel (OncoQual), which allows exploration of clinical data and real-time process and outcomes	needed to document reasons fo system would avoid incorrect di Objective: Evaluate the perform Outcome assessed: Adhereno breast cancer. Messures: Percentage of patier changes. Results: Tamoxfen use decrea 2000-to-2004 period to the 2006	ed to monitor compliance to na instances of noncompliance. ignosis code use by oncologis nance on OncoQual. to ASCO recommendations (ints receiving tamoxifen and an sed (76% vs. 50%) and aroma -to-2007 period, after the guid	Integration of EMR with the ts or staff.	explanatory codes are a billing information apy for hormone-positive nd after the guideline d (15% vs. 46%) from ed.		
oncology department in Italy ¹⁷ EMR includes a clinical instrument panel (OncoQual), which allows exploration of clinical data and real-time process and outcomes measurements	needed to document reasons fo system would avoid incorrect dia Objective: Evaluate the perform Outcome assessed: Achrenon breast cancer. Measures: Percentage of patien changes. Results: Tamotifen use decreas 2000-to-2004 period to the 2006 Conclusion: Collection and an time process-based measures is	et la monitar compliance la nei ristances di noncompliance, agnasis code use by ancologis ance an OncoQual. ta b ASCO recommendations or ths receiving tamoxifen and an sed (76% vs. 50%) and aroma -co2007 period, after the guid alysis of quality assessment de to daily clinical practice through	Integration of EMR with the ts or staff. an adjuvant endocrine there amatase inhibitors before a tase inhibitor use increase elines changed, as expect ta took few hours and allow h self-assessment.	explanatory codes are billing information apy for hormone-positive nd after the guideline d (15% vs. 46%) from ad.		
onicology department in Italy ¹⁷ EMR includes a clinical instrument panel (OncoQual), which allows exploration of clinical data and real-time process and outcomes measurements Use of EMR with an integrated weight-based dosing	needed to document reasons fo system would avoid incorrect du' Objective: Evaluate the perform Outcome assessed: Adherence breast cancer. Messures: Percentage of patien changes. Results: Tamoufen use decreas 2000-to:2004 period to the 2006 Conclusion: Collection and and time process-based messures in Goal: Assess impact of doaling of children.	ed to monitor compliance to no instancia of noncompliance, sgnosis code use by oncologis anarce on Oncoclual, e to ASCO recommendations of this receiving tamoxifen and an sed (76% vs. 50%) and aroma > 62007 period, after the guid alysis of quality assessment do ho daily clinical grantice throug alaculator integrated into EMR	Integration of EMR with the ts or staff. In adjuvant endocrine there constase inhibitors before a tase inhibitor use increase ellines changed, as expect ta took few hours and allow the self-assessment. on dosing errors for acetar	explanatory codes are billing information apy for hormone-positive nd after the guideline d (15% vs. 46%) from ad. ved incorporation of real- ninophen and ibuprofen i		
oncology department in Italy ¹⁷ EMR includes a clinical instrument panel (OncoQual), which allows exploration of clinical data and real-time process and outcomes measurements Use of EMR with an integrated	needed to document reasons fo system would avoid incorrect du' Objective: Evaluate the perform Outcome assessed: Adhrenon breast cancer. Messures: Percentage of patien changes. 2000-to:2004 period to the 2006 Conclusion: Collection and and time process-based mesaures in Goal: Assess impact of dosing Children. Results: Strength overdosing e 242 children (P = 0.028) after C	ed to monitor compliance to no instances of noncompliance, agrossis code use by oncologis to ASCO recommendations is to ASCO recommendations is to ASCO recommendations is the receiving tamoxifen and an exed (76% vs. 50%) and aroma head (76% vs. 50%) and (76% vs. 50%) head (76% vs. 50%) and (76% vs. 50%) head (76% vs. 50% vs. 50%) head (76% vs. 50%	Integration of EMR with the ts or staff. In adjuvant endocrine there contase inhibitors before a tase inhibitor use increase ellines changed, as expect ta took (wh hours and allow the self-assessment. on dosing errors for acetar hildren before calculator in	explanatory codes are a billing information apy for hormone-positive nd after the guideline di (15% vs. 46%) from di. ved incorporation of real- ninophen and ibuprofen tegration and 4.0% of		
oncology department in Italy ¹⁷ EMR includes a clinical instrument panel (OncoQual), which allows exploration of clinical data and real-time process and outcomes measurements Use of EMR with an integrated weight-based dosing calculator in a family medicine	needed to document reasons fo system would avoid incorrect dui Objective: Evaluate the perform Outcome assessed: Adherence treast cancer. Measures: Percentage of patient Results: Timorific use decreas 2000-1o-2004 period to the 2006 Conclusion: Collection and ann time process-based measures is Conclusion: Collection and ann time process-based measures is Coal: Assess Impact of dosing of children.	ed to monitor compliance to no instances of noncompliance, agrossis code use by oncologis to ASCO recommendations is to ASCO recommendations is to ASCO recommendations is the receiving tamoxifen and an exed (76% vs. 50%) and aroma head (76% vs. 50%) and (76% vs. 50%) head (76% vs. 50%) and (76% vs. 50%) head (76% vs. 50% vs. 50%) head (76% vs. 50%	Integration of EMR with the ts or staff. In adjuvant endocrine there contase inhibitors before a tase inhibitor use increase ellines changed, as expect ta took (wh hours and allow the self-assessment. on dosing errors for acetar hildren before calculator in	explanatory codes are a billing information apy for hormone-positive nd after the guideline di (15% vs. 46%) from di. ved incorporation of real- ninophen and ibuprofen tegration and 4.0% of		
oncology department in Italy ¹⁷ EMR Includes a clinical instrument panel (ChocoQal), which allows exploration of clinical data and real-time process and outcomes measurements Use of EMR with an integrated weight-based doing calculator in a family medicine clinic.	needs to document reasons to system world avoid incorrect di Opicitive: Evaluate he parton breast canoer. Measures: Percentage of paties changes. Results: Tamoifen use decrea 2006-to2004 period to the 2006 Conclusion: Colection and an time process-based measures in Conclusion: Colection and an time process-based measures in Conclusion: Colection and an time process-based measures in Conclusion: Weight-based of children. From poster authors: Dosing rugs requi	ed to monitor compliance to my instances of noncompliance, agnosis code use by oncologic mace on Oncoclustic to ASCO recommendations of the receiving tamosfer and any el (76% vs. 26%) and aronne ad (76% vs. 26%) and aronne h-b-2007 parios, affect the guid visios of guida seasement d ad cultator integrated in the EMR more soccurred in 8.9% of 316 6 locutator integrated into adaptation integrated into adaptation could be adaptation could be	Integration of EMR with the ts or staff. an adjuvant endocrine them omatase inhibitors before a tase inhibitor use increased lines changed, as expect ta took few hours and allow heef-assesment. on dosing errors for acetar hildren before calculator in the EMR program reduced	explanatory codes are billing information app for hormone-positive and after the guideline d (1% vs. 46%) from di, vs. 46%) from di, vs. 46%) from diversion and ibuprofen i ninophen and ibuprofen i tegration and 4.0% of medication errors in		
oncology department in taby ¹⁷ EMR includes a clinical instrument panel (ChocoCaul), which allows accidation of clinical data and real-time dimical data and real-time measurements Use of EMR with an integrated actuations of comes acculations of coding acculations	needed to document reasons fo system voud avoir and incomed di Objective: Evaluate he perform breast cancer. Measures: Percentage of patien changes. Results: Ticoponier use deras deras changes. Results: Strength overdoing of Conclusion: Collection and and me process-based measures is Ocat. Assess impact of cosing: Cale Assess impact of cosing Cale Assess impact	ed to monitor compliance to no instances of noncompliance, agrossis code use by oncologis ance on OncoQual. Is 0.ASCO recommendations of the sceleting tamoxifen and an edd (76% vs. 50%) and aroma edd (76% vs. 50%) and aroma edd (76% vs. 50%) and aroma alculator integrated the DEM alculator integrated into take and the sceleting alculator integrated into alculator integrated into alculator integrated into alculator integrated into alculator integrated one of DEMT alents analyzed.	Integration of EMR with the sign of EMR with the source of EMR and the inhibitors before a lease inhibitor before a lease inhibitor use increases elines changed, as expect as look fee hours and alloh a self-assessment. on dosing errors for acetar in define before calculator in hildren before calculator in the EMR program reduced useful in oncology practice	explanatory codes are billing information apy for hormone-positive and after the guideline of (15% vs. 46%) from diverse incorporation of real- weel incorporation of real- minophen and buprofen integration and 4.0% of medication errors in si 'EMRa because of the		
oncology department In Bay ¹⁷ EMR Includes a clinical instrument panel (DicocQual), instrument panel (DicocQual), dicinal data and reach of process and outcomes measurements Use of EMR with an integrated weight-based dosing accluator in a family medicine direct ² Providers were interviewed and EMR software was	needs to document reasons to system world avoid incorrect di objective: Evaluate in e perform breast cancer. Measures: Percentage of paties changes. Results: Tamosfen use decrea 2000-to-2004 period to the 2000 Conclusion: Colection and ant time process-based measures in Conclusion: Colection and ant time process-based measures in Conclusion: Colection and ant time process-based measures in Conclusion: Weight-based do children. From poster authors: Dosing Yanger Colection Minter of conclosing Yanger Seal - Poblem tractor to software is	ed to monitor compliance to mo- instances of noncompliance. Improvide the second second second second to the second second second second second the second second second second second second second second second second second to data second	Integration of EMR with the sign of EMR with the source of EMR and the inhibitors before a lease inhibitor before a lease inhibitor use increases elines changed, as expect as look fee hours and alloh a self-assessment. on dosing errors for acetar in define before calculator in hildren before calculator in the EMR program reduced useful in oncology practice	explanatory codes are billing information apy for hormone-positive and after the guideline of (15% vs. 46%) from diverse incorporation of real- weel incorporation of real- minophen and buprofen integration and 4.0% of medication errors in si 'EMRa because of the		
oncloby department in taby ¹⁷ EMR includes a clinical instrument panel (ChocoCaul), minimument panel (ChocoCaul), minimum and the panel panel process and outcomes measurements acculator in a family medicine dimic ³	needs to document reasons to system vould avoid incomed di Objective: Evaluate he parton Outcome assessed: Adhereno breast cance: Messures: Terroartage of patien changes. Results: Tamonifen use decision Conceluation: Collection and an Results: Strength overdoning of claiden. Results: Strength overdoning of claiden. Results: Strength overdoning of chalten. Data hand 11 terroises: Data for number of oncology drugs regult - Pacific maccol to software its - Pacific maccol to software its	ed to monitor compliance to mo- instances of noncompliance. Improvide the second second second second to the second second second second second the second second second second second second second second second second second to data second	Integration of EMR with the sign of EMR with the source of EMR and the inhibitors before a lease inhibitor before a lease inhibitor use increases elines changed, as expect as look fee hours and alloh a self-assessment. on dosing errors for acetar in define before calculator in hildren before calculator in the EMR program reduced useful in oncology practice	explanatory codes are billing information apy for hormone-positive and after the guideline of (15% vs. 46%) from diverse incorporation of real- weel incorporation of real- minophen and buprofen integration and 4.0% of medication errors in si 'EMRa because of the		
oncology department In Bay ¹⁷ EMR Includes a clinical instrument panel (DirocOut) instrument panel (DirocOut) of clinical data and real-time process and outcomes measurements Use of EMR with an integrated weight-based dosing weight-based dosing medicine. ¹⁰	needs to document reasons to system world avoid incorrect di objective: Evaluate in perform breast cancer Measures: Percentage of paties changes. Results: Tamosfen use decrea 2000-to-2004 period to the 2000 Conclusion: Colection and ant time process-based measures Conclusion: Colection and ant time process-based measures and distance of the system chaldren. From poster authors: Dosing founded in Problem tactor to software is a Poblem tactor to software is	ed to monitor compliance to ma instances of noncompliance, agrositic acide use by oncologie to ASCO recommendations of the ASCO recommendations of the receiving tamoxifen and an eded (76% vs. 55%) and aroma obsolved to acide the guid bysis of quality assessment (d acideutor integrated in the acideutor integrated in the acideutor integrated in the acideutor integrated into acideutor integrated into acideutor integrated into acideutor integrated into acideutor integrated down acideutor integrated down acideutor integrated into acideutor integrated down acideutor integrated acideutor acideutor acideutor acideutor acideutor acideutor acideutor acideutor acideutor acideutor acideutor acid	Integration of EMR with the so relation of EMR with the so relation of EMR with the source and the source and metals inhibitor before a source integration of the source and and the source and the source and the test of the holdren before calculator in the EMR program reduced useful in oncology practice provide the laboratory tec	explanatory codes are billing information app for hormone-positive and after the guideline of (15% v4.45%) from edi- licorporation of real- minophen and buproten tegration and 4.0% of medication errors in a' EMRs because of the hnician with the FOBT		

ASCO = American Society of Clinical Oncology; EMR = electronic medical records; FOBT = facal occult blood test; ICD = International Classification of Diseases, NCCN = National Comprehensive Cancer Network; NICCQ = National Initiative for Cancer Care Quality; NR = not reported; PCP = primary care physician.

CONCLUSIONS

- · EMR may be financially challenging for some small physician practices
- · Most medical records staff at cancer centers are made obsolete by EMR.
- · EMR can assist providers in assessing whether their patients are receiving guideline-adherent care and aid in more efficient processes of care, thereby improving overall quality of cancer care.
- · Patients generally do not view EMR as hindering their interactions with providers, despite some physicians' initial fears that this would be the case.
- · Based on nurses' negative experiences with EMR, more types of staff should be involved in the design process to increase efficiency gains and the number of willing users
- · Needed improvements in EMR design include the need to communicate with multiple devices and information systems
- · Continued monitoring of the EMR system is needed to ensure proper functioning (e.g., transmission of alerts).

References:

1. Meropol NJ, et al. J Clin Oncol 2007;25(2):180-186.

- 2 Pauly MV / Clin Oncol 2007:25(2):171-174
- 3. Committee on Quality of Health Care in America. Institute of Medicine Washington, DC: National Academy Press: 2001
- 4. Chao HH. et al. Clin Colorectal Cancer 2009;8(1):22-28
- 5. Fasola G. et al. J Clin Oncol (Meeting abstracts) 2006;24(18S);16028 6 Drohan B. et al. Breast / 2009;15(Suppl 1):S46-S55
- 7 Kim IV et al. Clin / ab Med 2009-29(3):449-461
- 8 Irani JS et al J Am Board Fam Med 2009:22(5):553-562
- 9. Hesita EL. J Clin Oncol (Meeting abstracts) 2006;24(18S):16043.
- 10 Sassen F.I. Comput Inform Nurs 2009:27(5):281-287 11. Vakil R. et al. J Clin Oncol (Meeting abstracts) 2007:25:6637. 12. Miller RH, et al. Health Aff (Millwood). 2005;24(5):1127-1137. 13. Kian LA, et al. Health Financ Manage 1995;49(7):58-60, 62, 64-67 14 Coscin AM, et al. J Clin Oncol (Meeting abstracts) 2008;26:6578
- 15. Dietrich LL. et al. J Clin Oncol (Meeting abstracts) 2007:25:6545. 16. Ebrahimi B, et al. J Clin Oncol (Meeting abstracts) 2008;26:17527. 17. Galligioni E, et al. J Clin Oncol (Meeting abstracts) 2009;27:6620. 18 Ginzburg R. et al. Am J Health Syst Pharm 2009;66(22):2037-204 19. Singh H, et al. BMC Med Inform Decis Mak 2009;9:49.

Contact Information

Shahnaz B. Khan, MPH Senior Director, Regulatory and Health Outcomes Strategy **RTI Health Solutions** 200 Park Office Drive Research Triangle Park, NC 27709 Phone: +1.919.485.2796 Fay: +1 010 541 7222 E-mail: skhan@rti.org